Pursuits
Bass Expands Drug Patent Fight as Celgene, Shire Make Five
This article is for subscribers only.
Hedge fund manager Kyle Bass has expanded the number of drug companies whose patents he has targeted to five.
In less than three months, Bass’s Coalition for Affordable Drugs has filed petitions to invalidate patents on six different drugs, including two on Thursday, owned by Shire Plc and Celgene Corp. His tactics are largely made possible by a change in U.S. law that, beginning in 2012, created new procedures to challenge patents, including by third parties.